Connect with us

Technology

High Throughput Screening (HTS) Market size is set to grow by USD 19.9 billion from 2024-2028, Rise in R and D investments to boost the market growth, Technavio

Published

2 years ago

on

NEW YORK, July 22, 2024 /PRNewswire/ — The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period.  Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies – Click for the snapshot of this report

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

Application (Target identification and validation, Primary and secondary screening, Toxicology assessment, and Stem cell research), End-user (Pharmaceutical and biotechnology companies, Academic and research institutes, and CROs), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Key Market Trends Fueling Growth

The High Throughput Screening (HTS) market faces unique challenges due to the specialized nature of its products and niche end-users. Brand and product visibility play a limited role in sales. Instead, vendors focus on enhancing their distribution networks and ensuring product availability. HTS advertising and marketing are restricted, and awareness is lacking. Thermo Fisher Scientific and Bio-Rad Laboratories use websites, documents, brochures, and interactive videos on YouTube to educate end-users. Workshops are also being conducted to increase awareness. Advanced product development is leading market participants to recognize the importance of promotional activities and awareness programs. These factors are expected to boost the global HTS market during the forecast period. 

High-throughput screening (HTS) is a key trend in the biotech industry, enabling researchers to test large compound libraries for potential drug candidates. Pharmaceutical corporations, biotech startups, academic institutions, and research organizations are leveraging HTS to tackle complex illnesses like cancer and neurological disorders. HTS involves using specialized equipment such as robotic arms, microplate readers, and high-resolution imaging systems for automating target identification and data analysis. Data analytics plays a crucial role in HTS, with machine learning and data management systems used for data organization, retrieval, integration, and storage. Carrier screening market and stem cell research also benefit from HTS. Drug repurposing initiatives, like Adcetris from Seagen, are gaining traction, and collaborative networks among HTS service providers facilitate open innovation models. The biopharmaceutical industry’s focus on precision medicine drives the demand for HTS, with companies investing in computing foundations and chemical databases to support genomic data analysis. Despite advancements, challenges such as false-positive findings and maintenance of specialized equipment persist. The global healthcare sector continues to embrace HTS, fueling growth in this market. Companies like Relay Therapeutics and Biotechnology startups are leading the charge in HTS-driven drug discovery. Toxicology and open innovation models further expand HTS applications. 

Discover 360° analysis of this market. For complete information, schedule your consultation- Book Here!

Market Challenges

The High Throughput Screening (HTS) market faces challenges due to the shortage of skilled professionals in pharmaceutical and biotechnology facilities and laboratories. HTS requires specialized expertise to operate the sensitive equipment and conduct tests effectively. In developing countries, the healthcare system lacks the necessary resources and trained personnel, which hinders the adoption of HTS technology. The absence of skilled technicians can lead to non-compliance, product failures, and significant financial losses for companies. Additionally, the poor healthcare infrastructure and low awareness about advanced technologies in these regions further impede the growth of the HTS market. Government investment in improving healthcare facilities and promoting awareness about HTS technology could help address these challenges and drive market expansion.The High-Throughput Screening (HTS) market is a significant segment of the biotechnology industry, serving the needs of pharma companies, research organizations, and biopharmaceutical industry players. The market faces challenges in areas like carrier screening, target identification, and drug repurposing initiatives. Machine learning and open innovation models are being adopted to overcome these challenges. Relay Therapeutics, a biotech startup, is leveraging HTS for drug discovery using cell-based assays and label-free technology. HTS involves using instruments like robotic arms and microplate readers, along with software and services for data management, storage, organization, retrieval, and integration. Consumables, chemical databases, genomic data, and detection techniques are essential components. HTS is used in stem cell research, toxicology, and precision medicine, and collaborative networks help share knowledge and resources. HTS service providers offer a range of products and services, including instruments, software, and consumables, to support drug development and clinical trials. Technology advancements include lab-on-a-chip and biochemical screening. The global healthcare sector stands to benefit significantly from these innovations.

For more insights on driver and challenges – Download a Sample Report

Segment Overview 

This high throughput screening (hts) market report extensively covers market segmentation by

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global High Throughput Screening (HTS) market is driven by the increasing burden of chronic diseases, such as cardiovascular diseases, cancer, and respiratory diseases, which necessitates early and comprehensive target identification and validation. Pharmaceutical companies are continuously outsourcing target identification and validation services to meet the rising demand for accurate analytical details on drugs and process development by regulatory agencies. The segment’s growth is further fueled by the increasing pipeline for biological candidates and advancements in target identification and validation using advanced bioinformatics tools, automated experimental designs, and AI and ML algorithms. These factors are expected to foster the growth of the target identification and validation segment in the global HTS market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 – 2022)  – Download a Sample Report

Learn and explore more about Technavio’s in-depth research reports

The global Toxicology Testing Market is experiencing significant growth due to rising awareness of drug safety and stringent regulatory policies. Meanwhile, the global Genome Editing Market is expanding rapidly, driven by advancements in CRISPR technology and increased investment in genetic research. Additionally, the global Modular Laboratory Automation Market is thriving as laboratories seek efficient, scalable solutions to enhance productivity and accuracy. Together, these markets represent pivotal areas in the biotechnology and healthcare sectors, fostering innovation and improving outcomes across various scientific and medical disciplines.

Research Analysis

High-throughput screening (HTS) is a critical technology in the field of drug discovery and research, enabling the rapid and efficient identification of potential therapeutic compounds. HTS utilizes large compound libraries, often numbering in the millions, to screen for compounds that exhibit desirable biological activity. Academic institutions and biotech startups collaborate with pharmaceutical corporations to leverage their expertise and resources in this area. Complex illnesses such as cancer and neurological disorders are major targets for HTS, with a focus on developing new treatments and repurposing existing drugs. Robotic arms, microplate readers, high-resolution imaging systems, and data management systems are essential tools in the HTS process. Data analytics plays a crucial role in organizing, retrieving, integrating, and storing data from HTS experiments. Chemical databases, research organizations, toxicology, open innovation models, and the global healthcare sector are also integral components of the HTS market. Adcetris from Seagen is an example of a successful drug discovered through HTS. Drug repurposing, stem cell research, and data retrieval are other areas of focus in the HTS market.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, retrieve, integrate, and analyze vast amounts of genomic data and chemical information. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives, such as those by Biotechnology startups like Relay Therapeutics, offer new opportunities for discovering existing drugs with potential applications for new diseases. The biopharmaceutical industry, global healthcare sector, and precision medicine are major markets for HTS, with a focus on detection techniques, clinical trials, and the development of products and services including consumables, software, and services. Technology advancements like cell-based assays, lab-on-a-chip, and label-free technology continue to drive innovation in HTS. Toxicology and stem cell research are also significant applications of HTS. Overall, HTS is a vital component of drug discovery and development, contributing to the advancement of new treatments for chronic diseases and other health conditions.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-size-is-set-to-grow-by-usd-19-9-billion-from-2024-2028–rise-in-r-and-d-investments-to-boost-the-market-growth-technavio-302202266.html

SOURCE Technavio

Related Topics:
Continue Reading

Technology

Axcelis Announces Financial Results for Third Quarter 2026

Published

6 minutes ago

on

November 5, 2026

By

Q3 2026 Highlights:

Revenue of $237.8 millionGAAP Gross Margin of 41.0%, and Non-GAAP Gross Margin of 41.2%GAAP Operating Margin of 11.5% and Non-GAAP Operating Margin of 16.6%GAAP Diluted Earnings Per Share of $1.21, and Non-GAAP Diluted Earnings Per Share of $1.26

BEVERLY, Mass., Nov. 5, 2026 /PRNewswire/ — Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the third quarter ended September 30, 2026.

President and CEO Russell Low commented, “We are pleased with our third quarter performance, as improving demand drove sequential growth in systems revenue, complemented by another quarterly record in CS&I. We are particularly encouraged by the strong increase in bookings, reflecting a broadening recovery across our end markets, with continued momentum in Memory and increasing activity in Power and General Mature. At the same time, we continue to see sustained strength in our CS&I business.”

Low added, “Our strategy of investing in next-generation technologies is beginning to yield tangible results and positions us well to capitalize on expanding market opportunities as customer investment recovers. We expect to finish 2026 with positive momentum and anticipate further growth in 2027.”

Senior Vice President and Interim CFO David Ryzhik stated, “Our third quarter results exceeded our expectations, supported by stronger shipments and record CS&I revenue, despite the impact from foreign exchange headwinds on our gross margin. We continue to generate healthy cash flow and maintain a strong balance sheet, providing us with ample financial flexibility. The combination of improving demand, a growing installed base and continued strength in CS&I provides a solid foundation as we enter 2027.”

Results Summary
(In thousands, except per share amounts and percentages)

Three months ended September 30,

2026

2025

Revenue

$

237,781

$

213,611

Gross margin

41.0 %

41.6 %

Operating margin

11.5 %

11.7 %

Net income

$

37,759

$

25,986

Diluted earnings per share

$

1.21

$

0.83

 

          Non-GAAP Results

Three months ended September 30,

2026

2025

Non-GAAP gross margin

41.2 %

41.8 %

Non-GAAP operating margin

16.6 %

18.2 %

Adjusted EBITDA

$

44,047

$

43,202

Non-GAAP net income

$

39,215

$

37,900

Non-GAAP diluted earnings per share

$

1.26

$

1.21

Business Outlook
For the fourth quarter ending December 31, 2026, Axcelis expects revenues of approximately $275 million, GAAP earnings per diluted share of approximately $1.15, and non-GAAP earnings per share of approximately $1.50.

Please refer to Fourth Quarter 2026 Outlook under the “Notes on our Non-GAAP Financial Information” section of this document for detail relating to the computation of non-GAAP earnings per diluted share as well as the Safe Harbor Statement section of this document.

Third Quarter 2026 Conference Call
The Company will host a call to discuss the results for the third quarter 2026 today at 8:30 a.m. ET. The call will be available via webcast that can be accessed through the Investors page of Axcelis’ website at www.axcelis.com, or by registering as a participant here: https://register-conf.media-server.com/register/BI02437563728a4138be5d107cd344f382 Webcast replays will be available for 30 days following the call.

Use of Non-GAAP Financial Results
This press release includes financial measures that are not presented in accordance with U.S. generally accepted accounting principles (“non-GAAP financial measures”). These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP other income, non-GAAP income tax provision, Adjusted EBITDA, non-GAAP net income, and non-GAAP diluted earnings per share, and reflect adjustments for the impact of share-based compensation expense, certain items related to restructuring and severance charges and any associated adjustments and transaction and integration costs associated with the merger agreement with Veeco Instruments announced on October 1, 2025.

Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP are provided in the financial tables included in this release.

For further information regarding these non-GAAP financial measures, please refer to the tables presenting reconciliations of our non-GAAP results to our GAAP results and the “Notes on Our Non-GAAP Financial Information” at the end of this press release.

Safe Harbor Statement
This press release contains, and the conference call will contain, forward-looking statements under the Private Securities Litigation Reform Act safe harbor provisions. These statements, which include our expectations for spending in our industry and guidance for future financial performance, are based on management’s current expectations and should be viewed with caution. They are subject to various risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are outside the control of the Company, including that customer decisions to place orders or our product shipments may not occur when we expect, that orders may not be converted to revenue in any particular quarter, or at all, whether demand will continue for the semiconductor equipment we produce or, if not, whether we can successfully meet changing market requirements, and whether we will be able to maintain continuity of business relationships with and purchases by major customers. Increased competitive pressure on sales and pricing, increases in material and other production costs that cannot be recouped in product pricing and instability caused by changing global economic, political or financial conditions, including with respect to the imposition of tariffs on our products or components of our products, could also cause actual results to differ materially from those in our forward-looking statements. These risks and other risk factors relating to Axcelis are described more fully in the most recent Form 10-K filed by Axcelis and in other documents filed from time to time with the Securities and Exchange Commission.

About Axcelis
Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 45 years. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

CONTACTS:

Investor Relations Contact:
David Ryzhik
Senior Vice President and Interim CFO
Telephone: (978) 787-2352
Email: David.Ryzhik@axcelis.com

Press/Media Relations Contact:
Maureen Hart
Senior Director, Corporate & Marketing Communications
Telephone: (978) 787-4266
Email: Maureen.Hart@axcelis.com

Axcelis Technologies, Inc.

Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three months ended 

Nine months ended

September 30,

September 30,

2026

2025

2026

2025

Revenue

237,781

213,611

651,912

600,718

Cost of revenue

140,357

124,805

382,717

335,802

Gross profit

97,424

88,806

269,195

264,916

Operating expenses:

Research and development

30,177

24,640

87,670

78,832

Sales and marketing

16,834

15,838

53,742

45,965

General and administrative

23,070

23,308

72,208

56,976

Total operating expenses

70,081

63,786

213,620

181,773

Income from operations

27,343

25,020

55,575

83,143

Other income (expense):

Interest income

7,422

5,465

16,459

16,547

Interest expense

(1,960)

(1,305)

(4,514)

(4,028)

Other, net

3,203

970

4,461

2,569

Total other income

8,665

5,130

16,406

15,088

Income before income taxes

36,008

30,150

71,981

98,231

Income tax (benefit) provision

(1,751)

4,164

1,717

12,290

Net income

$

37,759

$

25,986

$

70,264

$

85,941

Net income per share:

Basic

$

1.22

$

0.83

$

2.28

$

2.70

Diluted

$

1.21

$

0.83

$

2.26

$

2.70

Shares used in computing net income per share:

Basic weighted average shares of common stock

30,882

31,287

30,804

31,796

Diluted weighted average shares of common stock

31,105

31,450

31,089

31,863

Beginning in the third quarter of 2026, Axcelis will no longer separately present revenue and cost of revenue attributable to Services, which represents a small percentage of Axcelis’ overall business.

Axcelis Technologies, Inc.

Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

September 30,

December 31,

2026

2025

ASSETS

Current assets:

Cash and cash equivalents

$

190,769

$

145,451

Short-term investments

281,588

228,802

Accounts receivable, net

154,713

168,479

Inventories, net

376,341

329,010

Prepaid income taxes

7,604

4,658

Prepaid expenses and other current assets

88,935

66,802

Total current assets

1,099,950

943,202

Property, plant and equipment, net

59,468

56,146

Operating lease assets

27,993

28,927

Finance lease assets, net

13,198

14,154

Long-term restricted cash

10,638

10,627

Deferred income taxes

79,268

79,895

Long-term investments

142,982

182,396

Other assets

44,015

46,004

Total assets

$

1,477,512

$

1,361,351

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$

78,632

$

42,309

Accrued compensation

28,103

34,233

Warranty

10,615

9,516

Income taxes

5,873

11,383

Deferred revenue

95,620

65,494

Current portion of finance lease obligation

1,799

1,575

Other current liabilities

27,755

33,150

Total current liabilities

248,397

197,660

Long-term finance lease obligation

39,367

40,754

Long-term deferred revenue

42,424

43,445

Other long-term liabilities

34,090

44,815

Total liabilities

364,278

326,674

Stockholders’ equity:

Common stock, $0.001 par value, 75,000 shares authorized; 30,884 shares issued and outstanding at September 30, 2026; 30,717 shares issued and outstanding at December 31, 2025

31

31

Additional paid-in capital

542,467

533,309

Retained earnings

573,803

503,539

Accumulated other comprehensive loss

(3,067)

(2,202)

Total stockholders’ equity

1,113,234

1,034,677

Total liabilities and stockholders’ equity

$

1,477,512

$

1,361,351

 

Axcelis Technologies, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three months ended

Nine months ended

September 30,

September 30,

2026

2025

2026

2025

Cash flows from operating activities

Net income

$

37,759

$

25,986

$

70,264

$

85,941

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

4,489

4,328

13,364

13,152

Stock-based compensation expense

6,467

5,344

17,791

15,668

Other

(11,324)

6,907

(8,165)

(4,110)

Change in other assets and liabilities, net

2,830

2,785

(16,521)

14,221

Net cash provided by operating activities

40,221

45,350

76,733

124,872

Cash flows from investing activities

Expenditures for property, plant and equipment and capitalized software

(2,504)

(2,015)

(7,897)

(8,960)

Other changes in investing activities, net

(3,644)

3,393

(14,987)

46,194

Net cash (used in) provided by investing activities

(6,148)

1,378

(22,884)

37,234

Cash flows from financing activities

Repurchase of common stock

—

(32,335)

—

(95,850)

Other changes from financing activities, net

(558)

(440)

(9,806)

(4,022)

Net cash used in financing activities

(558)

(32,775)

(9,806)

(99,872)

Effect of exchange rate changes on cash and cash equivalents

2,263

(106)

1,286

1,829

Net increase in cash, cash equivalents and restricted cash

35,778

13,847

45,329

64,063

Cash, cash equivalents and restricted cash at beginning of period

165,629

181,280

156,078

131,064

Cash, cash equivalents and restricted cash at end of period

$

201,407

$

195,127

$

201,407

$

195,127

 

Axcelis Technologies, Inc. 

Schedule Reconciling Selected Non-GAAP Financial Measures

(In thousands, except per share amounts)

Three months ended September 30,

Nine months ended September 30,

2026

2025

2026

2025

GAAP gross Profit

$

97,424

$

88,806

$

269,195

$

264,916

Restructuring1

—

—

—

226

Stock-based compensation

605

499

1,802

1,421

Non-GAAP gross profit

$

98,029

$

89,305

$

270,997

$

266,563

Non-GAAP gross margin

41.2 %

41.8 %

41.6 %

44.4 %

GAAP operating expense

$

70,081

$

63,786

$

213,620

$

181,773

Transaction and integration2

(4,967)

(8,274)

(20,192)

(8,274)

Bad debt expense

—

—

(65)

—

Restructuring1

—

(236)

—

(1,130)

Other3

(781)

—

(781)

—

Stock-based compensation

(5,862)

(4,845)

(15,989)

(14,247)

Non-GAAP operating expense

$

58,471

$

50,431

$

176,593

$

158,122

GAAP operating income

$

27,343

$

25,020

$

55,575

$

83,143

Transaction and integration2

4,967

8,274

20,192

8,274

Bad debt expense

—

—

65

—

Restructuring1

—

236

—

1,356

Other3

781

—

781

—

Stock-based compensation

6,467

5,344

17,791

15,668

Non-GAAP operating income

$

39,558

$

38,874

$

94,404

$

108,441

Non-GAAP operating margin

16.6 %

18.2 %

14.5 %

18.1 %

GAAP other income (expense)

$

8,665

$

5,130

$

16,406

$

15,088

Discrete tax related items4

(1,726)

—

(1,726)

—

Non-GAAP other income

$

6,939

$

5,130

$

14,680

$

15,088

GAAP income tax (benefit) provision

$

(1,751)

$

4,164

$

1,717

$

12,290

Discrete tax related items4

7,565

—

7,565

—

Income tax effect of non-GAAP adjustments5 

1,468

1,940

5,194

3,542

Non-GAAP income tax provision

$

7,282

$

6,104

$

14,476

$

15,832

GAAP net income

$

37,759

$

25,986

$

70,264

$

85,941

Transaction and integration2

4,967

8,274

20,192

8,274

Bad debt expense

—

—

65

—

Restructuring1

—

236

—

1,356

Other3

781

—

781

—

Discrete tax related items4

(9,291)

—

(9,291)

—

Stock-based compensation

6,467

5,344

17,791

15,668

Income tax effect of non-GAAP adjustments5 

(1,468)

(1,940)

(5,194)

(3,542)

Non-GAAP net income

$

39,215

$

37,900

$

94,608

$

107,697

GAAP diluted EPS

$

1.21

$

0.83

$

2.26

$

2.70

Transaction and integration2

0.16

0.26

0.65

0.26

Bad debt expense

—

—

—

—

Restructuring1

—

0.01

—

0.04

Other3

0.03

—

0.03

—

Discrete tax related items4

(0.30)

—

(0.30)

—

Stock-based compensation

0.21

0.17

0.57

0.49

Income tax effect of non-GAAP adjustments5 

(0.05)

(0.06)

(0.17)

(0.11)

Non-GAAP diluted EPS

$

1.26

$

1.21

$

3.04

$

3.38

Note 1:

Restructuring and other costs primarily related to early retirement programs and severance costs, due to global cost-saving initiatives.

Note 2:

Transaction and integration costs include expenses associated with the merger agreement with Veeco Instruments, announced on October 1, 2025.

Note 3.

Other costs include miscellaneous tax related items.

Note 4.

Discrete items related to tax audits, including changes in uncertain tax positions and associated interest and penalties.

Note 5.

Impact of taxes from non-GAAP adjustments, uses adjusted tax rate of 14%.

Figures may not sum due to rounding.

 

Axcelis Technologies, Inc.

Reconciliation of Net Income to Adjusted EBITDA

(In thousands, except percentages)

Three months ended September 30,

Nine months ended September 30,

2026

2025

2026

2025

Net Income

$

37,759

$

25,986

$

70,264

$

85,941

Other (income) expense

(8,665)

(5,130)

(16,406)

(15,088)

Income tax (benefit) provision

(1,751)

4,164

1,717

12,290

Depreciation & amortization

4,489

4,328

13,364

13,152

Subtotal

31,832

29,348

68,939

96,295

Transaction and integration1

4,967

8,274

20,192

8,274

Bad debt expense

—

—

65

—

Restructuring2

—

236

—

1,356

Other3

781

—

781

—

Stock-based compensation

6,467

5,344

17,791

15,668

Adjusted EBITDA

$

44,047

$

43,202

$

107,768

$

121,593

Adjusted EBITDA margin

18.5 %

20.2 %

16.5 %

20.2 %

Note 1:

Transaction and integration costs include expenses associated with the merger agreement with Veeco Instruments, announced on October 1, 2025.

Note 2:

Restructuring and other costs primarily related to early retirement programs and severance costs, due to global cost-saving initiatives.

Note 3.

Other costs include miscellaneous tax related items.

 

Axcelis Technologies, Inc.

Fourth Quarter 2026 Outlook

GAAP to Non-GAAP Diluted Earnings Per Share

Three months ended

December 31, 2026

GAAP diluted EPS

$

1.15

Transaction and Integration1

0.19

Stock-based compensation

0.22

Income tax effect of non-GAAP adjustments2

(0.06)

Non-GAAP diluted EPS

$

1.50

Note 1:

Transaction and Integration costs include expenses associated with the merger agreement with Veeco Instruments, announced on October 1, 2025.

Note 2:

Impact of taxes from non-GAAP adjustments, uses adjusted tax rate of 14%.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/axcelis-announces-financial-results-for-third-quarter-2026-302930211.html

SOURCE Axcelis Technologies, Inc.

Continue Reading

Technology

Eventus wins Best Market, Trade or Communications Surveillance Solution in Regulation Asia Awards for Excellence 2026

Published

6 minutes ago

on

November 5, 2026

By

AUSTIN, Texas and HONG KONG, Nov. 5, 2026 /PRNewswire/ — Eventus, a leading provider of comprehensive, at-scale trade surveillance and financial risk solutions, last night won the award for Best Market, Trade or Communications Surveillance Solution for its Validus platform at the ninth annual Regulation Asia Awards for Excellence. The firm and its platform have now earned eight honors in the rigorous awards program since 2021.

A member of the independent judging panel said: “Eventus offers the best balance of detailed abuse detection, multi-asset scale, explainable alert automation and material advances over the past twelve months.”

Eventus CEO Cameron Routh said: “Market participants across the Asia-Pacific region face increased scrutiny of market conduct, supervisory controls, algorithmic trading, cross-market manipulation and alert governance. These firms often trade across multiple venues, asset classes, desks and jurisdiction, making it extremely difficult to maintain consistent and robust surveillance for those companies using fragmented or legacy systems. We’re delighted to earn another Regulation Asia Award for solving the challenges encountered by our clients conducting business in the region through a single, configurable surveillance environment.”

Bradley Maclean, Chair of the Awards Committee, Regulation Asia, said: “Surveillance teams need to know why an alert fired. Eventus backed every abuse typology with a clear detection mechanism, and managed false positives with discipline.”

The Regulation Asia Awards for Excellence celebrate financial institutions, technology providers, regulators, policymakers and advisory firms driving progress in compliance, managing risks, fostering resilience and safeguarding market integrity. By addressing the region’s unique regulatory challenges and evolving landscape, the leading firms are “shaping a stronger, more sustainable financial ecosystem for Asia,” Regulation Asia says, and the awards provide a platform to honor those driving innovation and leading efforts to manage risk, enhance resilience and uphold the integrity of Asia’s financial system. The independent judging panel for the Regulation Asia Awards for Excellence included seasoned practitioners at the forefront of regulatory, compliance and policymaking.

Eventus has clients on six continents surveilling multiple asset classes, including 30 active clients in the Asia-Pacific region, ranging from brokerage firms, to proprietary trading firms and digital asset marketplaces. More than half of Eventus’ new global clients have a presence in APAC.

Eventus has earned 18 honors for its work in the APAC region, including Market Surveillance Solution of the Year at the FOW Asia Pacific Awards in September and Best Trade Surveillance Solution at A-Team Group’s Capital Markets Technology Awards APAC. The firm has won 57awards and honors since 2018, including last month’s AI in Capital Markets Award for Best AI Solution for Trade Surveillance, as well as the Risk Technology Award for Trade Surveillance Product of the Year.

About Eventus 

Eventus provides state-of-the-art, at-scale trade surveillance software across all lines of defense. Its powerful, award-winning Validus platform is easy to deploy, customize and operate across equities, options, futures, foreign exchange (FX), fixed income, digital asset and prediction/information markets. Validus is proven in the most complex, high-volume, and real time environments of Eventus’ rapidly growing client base, including tier-1 banks, broker-dealers, futures commission merchants (FCMs), proprietary trading groups, market centers, buy-side institutions, energy and commodity trading firms, and regulators. Clients rely on the platform, coupled with the firm’s responsive support and product development, to overcome their most pressing trade surveillance regulatory challenges. For more, visit www.eventus.com.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eventus-wins-best-market-trade-or-communications-surveillance-solution-in-regulation-asia-awards-for-excellence-2026-302930394.html

SOURCE Eventus

Continue Reading

Technology

Rubrik’s Authorized Intelligence podcast joins the N2K CyberWire network

Published

6 minutes ago

on

November 5, 2026

By

Exploring the human side of resilience in the age of frontier AI.

FULTON, Md., Nov. 5, 2026 /PRNewswire/ — N2K Networks today announced that Authorized Intelligence, the new premier podcast from Rubrik, will join the N2K CyberWire podcast network. Hosted by AI risk management expert Cal Al-Dhubaib, the podcast features conversations with leading voices across the AI ecosystem on how organizations can embrace frontier AI opportunities while navigating an increasingly complex security landscape.

Rubrik launches the Authorized Intelligence podcast featuring conversations with leading voices across the AI ecosystem.

As frontier AI transforms how organizations operate, technology and security leaders must navigate emerging tools while collaborating across increasingly diverse functions. Authorized Intelligence brings listeners unique perspectives from threat researchers, security practitioners, AI builders, and policymakers to share firsthand experiences, challenge assumptions, and explore what works in practice. Through these conversations, the podcast examines the human decisions, collaboration, and shared understanding needed to build resilience in an AI-powered world.

“AI is fundamentally changing how organizations operate, and navigating that change requires learning from the people confronting these challenges, while making the difficult decisions,” said Peter Kilpe, CEO of N2K Networks. “We’re excited to continue our partnership with Rubrik through Authorized Intelligence, connecting our audience with the insights and perspectives shaping AI resilience.”

“Authorized Intelligence podcast is dedicated to security and technology leaders caught between unlocking the value of AI and controlling its risks.” said John Koo, CMO of Rubrik,  “From the AI systems leaders deploy to the attackers looking to use AI against them, Cal taps his decade of expertise in building AI for some of the most regulated industries to uncover a new reality with experts defining cyber resilience in the age of AI.”

The first three episodes of Authorized Intelligence are now available:

Episode 1: Red teaming with frontier models with Nidhi Aggarwal, Chief Product Officer, HackerOneEpisode 2: Solving AI board paralysis with Dominique Shelton Leipzig, CEO, Global Data Innovation and advisor to Fortune 500 boardsEpisode 3: Evaluating the safety and reliability of frontier models with Peter Gostev, AI Capability Lead, Arena.ai

New episodes of Authorized Intelligence air every two weeks on Tuesday. To hear the latest episode, listen and subscribe wherever you get your favorite podcasts or visit the N2K CyberWire website to explore the series.

About Rubrik
Rubrik (RBRK), the Security and AI Operations Company, leads at the intersection of data protection, cyber resilience, and enterprise AI acceleration. Rubrik Security Cloud delivers complete cyber resilience by securing, monitoring, and recovering data, identities, and workloads across clouds. Rubrik Agent Cloud accelerates trusted AI agent deployments at scale by monitoring and auditing agentic actions, enforcing real-time guardrails, fine-tuning for accuracy and undoing agentic mistakes. For more information, please visit www.rubrik.com.

About N2K Networks
From news to knowledge, N2K delivers critical industry insights, strategic intelligence, and performance-driven learning products that empower cybersecurity professionals to adapt, grow, and lead with confidence in an ever-evolving industry. Trusted by the most influential leaders and operators, N2K collaborates with the world’s top training and knowledge platforms, and partners with organizations ranging from Fortune 100 enterprises to fast-growing startups. N2K and its brands like N2K CyberWire connect the cybersecurity ecosystem and help security businesses and professionals grow.

Visit N2K.com to discover more about our learning products and enterprise offerings. Sign up for our industry leading podcasts and newsletters at N2K CyberWire.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rubriks-authorized-intelligence-podcast-joins-the-n2k-cyberwire-network-302929879.html

SOURCE N2K Networks

Continue Reading

Trending